An outbreak of concurrent echovirus 30 and coxsackievirus A1 infections associated with sea swimming among a group of travelers to Mexico.

BACKGROUND Enteroviruses are shed in human stool and can cause a wide spectrum of illness. They are the leading cause of aseptic meningitis. METHODS In 2004, the Connecticut Department of Public Health investigated a meningitis cluster among persons returning from a school-organized trip to Mexico. RESULTS Among 29 travelers (25 teenagers and 4 adult chaperones), 21 became acutely ill. Viral culture and nucleic acid amplification testing of stool (n=27) and cerebrospinal fluid (n=4) specimens identified enteroviral infection in 20 of 28 travelers from whom any specimen was obtained; 4 had echovirus 30 only, 11 had coxsackievirus (CV) A1 only, 4 had both echovirus 30 and CVA1, and 1 had CVA5 only. Illness onset dates were tightly clustered 4 days after a prolonged swim in the Gulf of Mexico. Time spent swimming was significantly associated with the odds of enteroviral infection (univariate odds ratio for each additional hour swimming, 14.3; 95% confidence interval, 1.3-154.3). Headache, fever, vomiting, and nausea occurred more frequently among the echovirus 30-infected travelers than among the uninfected control subjects (P< .05). The most frequent symptoms among travelers infected with only CVA1 identified were nausea and diarrhea (36% each), but neither was significantly associated with CVA1 infection; 5 patients with CVA1 infection were asymptomatic. CONCLUSIONS We identified multiple enteroviruses among the travelers. Clustered illness onsets suggest point-source exposure, which likely was a sea swim in sewage-contaminated seawater. Novel molecular amplification and sequencing methodologies were required to recognize the rarely identified CVA1, but it is ambiguous whether CVA1 infection caused illness. Travelers should be aware of risks associated with swimming in natural waters when visiting areas where there is limited sewage treatment.

[1]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  J. Wingard,et al.  Changes in causes of death over time after treatment for invasive aspergillosis , 2008, Cancer.

[3]  J. Perfect,et al.  When primary antifungal therapy fails. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  J. Wingard Learning from our failures: the antifungal treatment conundrum. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  H. Macapinlac,et al.  The use of 18F-fluorodeoxyglucose positron emission tomography for the diagnosis and management of invasive mould infections. , 2008, Medical mycology.

[6]  T. Hohl,et al.  Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure. , 2007, The Journal of infectious diseases.

[7]  J. Wagner,et al.  A scheme for defining cause of death and its application in the T cell depletion trial. , 2007, Biology of Blood and Marrow Transplantation.

[8]  B. Barlogie,et al.  Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis , 2007, Cancer.

[9]  B. Barlogie,et al.  Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications , 2007, Cancer.

[10]  J. Perfect,et al.  Immune reconstitution syndrome associated with opportunistic mycoses. , 2007, The Lancet. Infectious diseases.

[11]  J. Perfect,et al.  Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  D. Kontoyiannis,et al.  Pretreatment with Empty Liposomes Attenuates the Immunopathology of Invasive Pulmonary Aspergillosis in Corticosteroid-Immunosuppressed Mice , 2006, Antimicrobial Agents and Chemotherapy.

[13]  K. Sepkowitz,et al.  Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  Mark A Pallansch,et al.  Morbidity and Mortality Weekly Report Editorial and Production Staff Vol. 55 / Ss-8 Surveillance Summaries 1 Enterovirus Surveillance — United States, 1970–2005 , 2022 .

[15]  M. Pallansch,et al.  Sensitive, Seminested PCR Amplification of VP1 Sequences for Direct Identification of All Enterovirus Serotypes from Original Clinical Specimens , 2006, Journal of Clinical Microbiology.

[16]  J. Fine,et al.  Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  G. Fink,et al.  A Drug-Sensitive Genetic Network Masks Fungi from the Immune System , 2006, PLoS pathogens.

[18]  F. Dromer,et al.  Immune reconstitution inflammatory syndrome in HIV-infected patients with disseminated histoplasmosis , 2006, AIDS.

[19]  D. Kontoyiannis,et al.  Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). , 2006, Haematologica.

[20]  R. Rubin,et al.  Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  M. Pallansch,et al.  Enterovirus molecular detection and typing , 2005 .

[22]  B. Alexander,et al.  Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  F. Dromer,et al.  Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France , 2005, AIDS.

[24]  S. Shelburne,et al.  The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  M. Pallansch,et al.  Enteroviruses 76, 89, 90 and 91 represent a novel group within the species Human enterovirus A. , 2005, The Journal of general virology.

[26]  C. Montagnoli,et al.  Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. , 2005, The Journal of antimicrobial chemotherapy.

[27]  S. Cesaro,et al.  Combination antifungal therapy for invasive aspergillosis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  M. Czuczman,et al.  Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: Clinical, radiologic, and pathologic characteristics , 2005, Mycopathologia.

[29]  S. Diedrich,et al.  An outbreak of viral meningitis associated with a public swimming pond , 2004, Epidemiology and Infection.

[30]  D. Denning,et al.  Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  M. Pallansch,et al.  Molecular identification and characterization of two proposed new enterovirus serotypes, EV74 and EV75. , 2004, The Journal of general virology.

[32]  C. Viscoli Combination therapy for invasive aspergillosis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  S. Balajee,et al.  Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. , 2004, The Journal of infectious diseases.

[34]  E. Estey,et al.  β-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome , 2004 .

[35]  N. White,et al.  Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial , 2004, The Lancet.

[36]  C. Yiannoutsos,et al.  Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  W. Leisenring,et al.  Cyclophosphamide metabolism is affected by azole antifungals. , 2004, Blood.

[38]  J. Hadler,et al.  Aseptic meningitis outbreak associated with echovirus 9 among recreational vehicle campers--Connecticut, 2003. , 2004, MMWR. Morbidity and mortality weekly report.

[39]  C. Baker,et al.  Red book®: 2003 report of the committee on infectious diseases. , 2016 .

[40]  H. Fricker-Hidalgo,et al.  Detection of Circulating Aspergillus fumigatus Galactomannan: Value and Limits of the Platelia Test for Diagnosing Invasive Aspergillosis , 2003, Journal of Clinical Microbiology.

[41]  J. Perfect,et al.  Voriconazole treatment for less-common, emerging, or refractory fungal infections. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  J. Powers,et al.  Forum report: issues in the evaluation of diagnostic tests, use of historical controls, and merits of the current multicenter collaborative groups. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  J. Powers,et al.  Forum report: issues in the design of trials of drugs for the treatment of invasive aspergillosis. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  J. Powers,et al.  Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  M. Pallansch,et al.  Improved molecular identification of enteroviruses by RT-PCR and amplicon sequencing. , 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[46]  A. Bruu,et al.  Enteroviruses: Polioviruses, Coxsackieviruses, Echoviruses and Newer Enteroviruses , 2003 .

[47]  M. Landry,et al.  Rapid Enterovirus RNA Detection in Clinical Specimens by Using Nucleic Acid Sequence-Based Amplification , 2003, Journal of Clinical Microbiology.

[48]  J. Gerberding,et al.  Outbreaks of aseptic meningitis associated with echoviruses 9 and 30 and preliminary surveillance reports on enterovirus activity--United States, 2003. , 2003, MMWR. Morbidity and mortality weekly report.

[49]  J. Perfect,et al.  Comparison of caspofungin and amphotericin B for invasive candidiasis. , 2002, The New England journal of medicine.

[50]  D. Beek,et al.  Dexamethasone in adults with bacterial meningitis , 2002 .

[51]  Richard Sylvester,et al.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.

[52]  D. Bamberger,et al.  Safety and Efficacy of Liposomal Amphotericin B Compared with Conventional Amphotericin B for Induction Therapy of Histoplasmosis in Patients with AIDS , 2002, Annals of Internal Medicine.

[53]  B. François,et al.  Invasive Aspergillosis in Allogeneic Stem Cell Transplant Recipients: Increasing Antigenemia Is Associated with Progressive Disease , 2002 .

[54]  R. Hafner,et al.  Antigen Clearance during Treatment of Disseminated Histoplasmosis with Itraconazole versus Fluconazole in Patients with AIDS , 2002, Antimicrobial Agents and Chemotherapy.

[55]  D. Denning,et al.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[56]  M. Mulders,et al.  Viral water contamination as the cause of aseptic meningitis outbreak in Belarus. , 2001, Central European journal of public health.

[57]  J. Verhaegen,et al.  Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. , 2001, Blood.

[58]  A. Bernard,et al.  Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  A. Catanzaro,et al.  Comparison of Oral Fluconazole and Itraconazole for Progressive, Nonmeningeal Coccidioidomycosis , 2000, Annals of Internal Medicine.

[60]  Paul L. Williams,et al.  Practice Guidelines for the Treatment of Coccidioidomycosis , 2000 .

[61]  J. Perfect,et al.  Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[62]  W. Ledermann,et al.  Randomized trial of four vs. seven days of ceftriaxone treatment for bacterial meningitis in children with rapid initial recovery , 2000, The Pediatric infectious disease journal.

[63]  O. Lehtonen,et al.  Aspergillus antigen in serum, urine and bronchoalveolar lavage specimens of neutropenic patients in relation to clinical outcome. , 2000, Scandinavian journal of infectious diseases.

[64]  J. Cleary,et al.  Amphotericin B-induced interleukin-1beta expression in human monocytic cells is calcium and calmodulin dependent. , 1999, The Journal of infectious diseases.

[65]  C. Brisson,et al.  Job strain and pregnancy-induced hypertension. , 1999, Epidemiology.

[66]  J S Witte,et al.  The health effects of swimming in ocean water contaminated by storm drain runoff. , 1999, Epidemiology.

[67]  G. Mccracken,et al.  Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Meropenem Meningitis Study Group. , 1999, The Pediatric infectious disease journal.

[68]  S. Solomon,et al.  Viral meningitis in child care center staff and parents: an outbreak of echovirus 30 infections. , 1999, Public health reports.

[69]  M. Saag,et al.  A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[70]  A. Prüss Review of epidemiological studies on health effects from exposure to recreational water. , 1998, International journal of epidemiology.

[71]  M. Saag,et al.  Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. , 1997, The American journal of medicine.

[72]  M. Saag,et al.  Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. , 1997, The New England journal of medicine.

[73]  K. Kawakami,et al.  Anticryptococcal effect of amphotericin B is mediated through macrophage production of nitric oxide , 1996, Antimicrobial agents and chemotherapy.

[74]  J. Galgiani,et al.  Is It Ever Safe To Stop Azole Therapy for Coccidioides immitis Meningitis? , 1996, Annals of Internal Medicine.

[75]  K. Kliche,et al.  Infusion‐related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels , 1995, Mycoses.

[76]  J. Serody,et al.  Intravascular Catheter Exchange and Duration of Candidemia , 1995 .

[77]  R. Dagan,et al.  Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group , 1995, Antimicrobial agents and chemotherapy.

[78]  F. Hecht,et al.  Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. , 1995, The American journal of medicine.

[79]  G. Mccracken,et al.  Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children , 1995, Antimicrobial agents and chemotherapy.

[80]  J. Galgiani,et al.  Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. NIAID Mycoses Study Group. , 1995, The American journal of medicine.

[81]  A. Favero,et al.  Fatal haemoptysis in pulmonary filamentous mycosis: an underevaluated cause of death in patients with acute leukaemia in haematological complete remission. A retrospective study and review of the literature , 1995, British journal of haematology.

[82]  F. Kee,et al.  A community outbreak of echovirus infection associated with an outdoor swimming pool. , 1994, Journal of public health medicine.

[83]  M. Pallansch,et al.  Echovirus 30 infection and aseptic meningitis in parents of children attending a child care center. , 1994, The Journal of infectious diseases.

[84]  J. Galgiani,et al.  Fluconazole Therapy for Coccidioidal Meningitis , 1993, Annals of Internal Medicine.

[85]  M. Pallansch,et al.  Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[86]  B. Katz,et al.  Histoplasmosis relapse in patients with AIDS: detection using Histoplasma capsulatum variety capsulatum antigen levels. , 1991, Annals of internal medicine.

[87]  K. Olsen,et al.  The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. , 1991, The New England journal of medicine.

[88]  H. Rotbart Nucleic acid detection systems for enteroviruses , 1991, Clinical Microbiology Reviews.

[89]  J. Galgiani,et al.  Itraconazole treatment of coccidioidomycosis , 1990 .

[90]  R. M. Tucker,et al.  Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations. , 1990, Journal of the American Academy of Dermatology.

[91]  M. Salimans,et al.  Rapid and simple method for purification of nucleic acids , 1990, Journal of clinical microbiology.

[92]  R. M. Tucker,et al.  Itraconazole therapy for chronic coccidioidal meningitis. , 1990, Annals of internal medicine.

[93]  G. Potente CT findings in fungal opportunistic pneumonias: body and brain involvement. , 1989, Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society.

[94]  D. Lenaway,et al.  An outbreak of an enterovirus-like illness at a community wading pool: implications for public health inspection programs. , 1989, American journal of public health.

[95]  S. Lipson,et al.  Sensitivity of rhabdomyosarcoma and guinea pig embryo cell cultures to field isolates of difficult-to-cultivate group A coxsackieviruses , 1988, Journal of clinical microbiology.

[96]  J. Galgiani,et al.  Ketoconazole therapy of progressive coccidioidomycosis. Comparison of 400- and 800-mg doses and observations at higher doses. , 1988, The American journal of medicine.

[97]  L. Anderson,et al.  Temporal and geographic patterns of isolates of nonpolio enterovirus in the United States, 1970-1983. , 1986, The Journal of infectious diseases.

[98]  S. Albelda,et al.  Pulmonary cavitation and massive hemoptysis in invasive pulmonary aspergillosis. Influence of bone marrow recovery in patients with acute leukemia. , 2015, The American review of respiratory disease.

[99]  W. Gefter,et al.  Invasive pulmonary aspergillosis and acute leukemia. Limitations in the diagnostic utility of the air crescent sign. , 1985, Radiology.

[100]  E. H. Lennette Laboratory diagnosis of viral infections , 1985 .

[101]  K. R. Ratzan Viral meningitis. , 1985, The Medical clinics of North America.

[102]  D. Stevens,et al.  Experience with ketoconazole in three major manifestations of progressive coccidioidomycosis. , 1983, The American journal of medicine.

[103]  C. Madeley FATAL DIARRHOEA AND COXSACKIE A1 VIRUS , 1982, The Lancet.

[104]  R. Yolken,et al.  OUTBREAK OF COXSACKIE A1 GASTROENTERITIS: A COMPLICATION OF BONE-MARROW TRANSPLANTATION , 1982, The Lancet.

[105]  E. H. Lennette,et al.  Propagation and isolation of group A coxsackieviruses in RD cells , 1975, Journal of clinical microbiology.

[106]  C. A. Phillips,et al.  Coxsackievirus B epidemic at a Boy's Summer Camp. Isolation of virus from swimming water. , 1973, JAMA.

[107]  J. Enders,et al.  Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.

[108]  W. B. King THE LABORATORY DIAGNOSIS OF VIRAL INFECTIONS. , 1964, Maryland state medical journal.

[109]  W. Schaffner,et al.  The diarrhea of travelers. IV. Viral studies of visiting students in Mexico with further bacteriologic and parasitologic observations. , 1963, The American journal of tropical medicine and hygiene.

[110]  Gelfand Hm The occurrence in nature of the Coxsackie and ECHO viruses. , 1961 .

[111]  H. Gelfand The occurrence in nature of the Coxsackie and ECHO viruses. , 1961, Progress in medical virology. Fortschritte der medizinischen Virusforschung. Progres en virologie medicale.

[112]  B. Kean,et al.  The diarrhea of travelers. III. Drug prophylaxis in Mexico. , 1959, The New England journal of medicine.